The Accatur Companies have three specific business segments:
1. Accatur Biotech
In 2014, Accatur Biotech developed a portable gas chromatography/ flame ionization prototype system, including an auto-sampler and a lab information system, to test urine specimens for various licit and illicit drugs. Accatur Biotech is currently under discussions with end users to re-format the system into a "plug and play" system able to test saliva, blood and urine specimens for a broad spectrum of drugs for both clinical and non-clinical uses, for both qualitative ("are there drugs present") and quantitation ("how much drug is present") purposes. The system's data accumulation and integrated data analysis capabilities can be customized to operate as an information collection and disbursement network as needed by an end user.
Ellen Palm-Leis, the sole owner of the Accatur Companies, is a recognized expert in the interpretation of drug testing data and understanding the uses (and abuses) of scientific instrumentation used in drug testing programs. See, e.g., Ms. Palm-Leis' article, "False Positive? The Reality Of Workplace Drugs In America" at http://www.huffingtonpost.com/2013/12/31/workplace-drugs-testing_n_4524048.html
The Accatur System is versatile enough to meet the specific needs of all drug testing providers and can be customized for the needs of clinical/diagnostic uses in healthcare, for employment drug screening purposes and for the needs of different segments of the law enforcement community.
2. Accatur BioPharm
Accatur BioPharm affiliates not only provide consulting services to other labs, Accatur affiliates are also working with University of California Medical School and Pharmacology professors on pharmaceutical products, including non-addicting patent and patent-pending formulations for stress and anxiety, depression and pain, with a view towards replacing impairment inducing and addictive benzodiazepines, tri-cyclic anti-depressants and opioid/opiate based pain medications. The affiliates are also working on a non-addictive, a patented formula for an allo-steroid modulator that enhances brain receptor functions (i.e., a cognition deficit improvement formulation) that has been awarded several NIH grants to date for traumatic brain injury and schizophrenia, but also looks positive for further development as a treatment therapy for patients suffering from Alzheimer's Disease. The affiliates also hold a patented "anti-spasmodic/anti-seizure" formula that improves on an out-of-patent formulation that was unable to resolve certain issues that we have now resolved.
3. Accatur Laboratories
The laboratories at Accatur Diagnostics I and II provide Medicare, American Medical Association ("AMA"), American College of Occupational and Environmental Medicine ("ACOEM") and Official Disability Guidelines ("ODG") mandated independent toxicology (Drug Compliance) screening programs for physicians and clinics managing acute and chronic pain patients and psychiatric patients currently prescribed or being considered for amphetamine, benzodiazepines, tri-cyclic anti-depressants, and/or opiate and opioid medications as part of their treatment therapies. The laboratories also set up and manage drug screening programs for facilities specializing in detox, sober living, rehabilitation and out-patient services to drug users and abusers and others who have suffered from drug dependence. Typically the target population has used or is using DEA scheduled drugs; they will have been injured on the job (i.e., subject to the mandates of a state's workers compensation system), involved in a personal injury accident, receiving long term disability benefits from an on-going medical condition or suffered from recreational use or prescribed use of addictive drugs. Per the AMA Guidelines, the ACOEM and ODG Guidelines, the California Per the AMA Guidelines, the ACOEM and ODG Guidelines, the California Medical Treatment Utilization Standards ("MTUS") for California residents with injuries caused by or arising from work and the standards set by the American Academy of Pain Management for patients on opioid pain medication as part of their paid treatment therapy, and for persons in intensive outpatient programs for recovery from drug dependence, random and regular drug screening- a/k/a toxicology screening- is "medically necessary" and prescribed under "evidence-based medicine" rules as a treatment therapy component utilized to ensure patients adhere to physician orders, do not over- or under- or self-medicate, and do not abuse both prescribed and non-prescribed drugs. The Accatur laboratories in La Quinta, CA and Irvine, CA provide customized drug screening and specimen integrity programs developed hand-in-hand with physician, clinic and Intensive Out Patient healthcare business clients.
In addition to providing drug screening services for clinical and diagnostic purposes to the healthcare communities, using an array of technologies, the Accatur Diagnostics II laboratory in Irvine also (1) provides unique and individualized lab services to NIH ("National Institutes of Health") funded R&D recipients on projects involving central nervous system pharmaceutical modalities and (2) acts as a beta-testing and R&D laboratory for cutting edge scientific instrumentation and lab technology (such as a lab and hospital grade nitrogen production system that delivers nitrogen up to 6x faster than current membrane technology and the small foot-print, lightweight, portable real-time gas chromatography system described above for urine specimen drug testing).
Random and regular toxicology drug screening is a requirement and not an option for all patients who are being prescribed Opioid Medications according to the Chronic Pain Chapters of both ACOEM, ODG and various other state medical guidelines and laws.
Evidence Based Medicine and Medical Necessity:
American College of Occupational and Environmental Medicine (ACOEM):
The drug tests are conducted by Accatur predicated on ACOEM guidelines set forth in Chapter 5, Table 5-1 under the Occupational Medicine Practice Guidelines: Evaluation and Management of Common Health Problems and Functional Recovery in Workers, 2nd Edition. References recommending random drug testing include: Chelminski, Multi-disciplinary Pain Management Criteria: (Chelminski, 2005) indicates the criteria used to define serious substance misuse in a multi-disciplinary pain management program include one or more of the following: (a) cocaine or amphetamines on urine toxicology screen (positive cannabinoid was not considered serious substance abuse); (b) procurement of opioids from more than one provider on a regular basis; (c) diversion of opioids; (d) urine toxicology screen negative for prescribed drugs on at least two occasions (an indicator of possible diversion); and (e) urine toxicology screen positive on at least two occasions for opioids not routinely prescribed.
Official Disability Guidelines (ODG):
Per the Official Disability Guidelines- ODG Treatment in Workers' Compensation, Pain Chapter (2009), Chronic Pain Medical Treatment Guidelines- Drug Testing (pg. 43), ODG recommends toxicology drug screening to differentiate between dependence and addiction with opioids and indicates the screening instruments which have been developed or are in the development stages to aid in differentiation between drug dependence and addiction. Urinalysis testing is at the head of the list. See also sections on "Opioids, red flags for addiction;" "Opioids, screening for risk of addiction;" "Opioids, patients at high-risk for misuse;" and "Substance abuse (tolerance, dependence, addiction)."
© 2011 Accatur Diagnostics, an Accatur Company